Evidence map›Paper›PMID 40097914›Full record

ArticleThe Journal of small animal practice2025

Pharmacokinetics of GS-441524 following intravenous remdesivir in six cats and results of therapeutic drug monitoring during treatment of feline infectious peritonitis: 22 cases (2021-2024).

S J Coggins, M Govendir, J M Norris, R Malik, E J Hall, M F Thompson, B Kimble

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of small animal practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

S J CogginsFaculty of Science, Sydney School of Veterinary Science, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0001-8683-5014
M GovendirFaculty of Science, Sydney School of Veterinary Science, The University of Sydney, Sydney, New South Wales, Australia.
J M NorrisFaculty of Science, Sydney School of Veterinary Science, The University of Sydney, Sydney, New South Wales, Australia.
R MalikCentre for Veterinary Education, The University of Sydney, Sydney, New South Wales, Australia.
E J HallFaculty of Science, Sydney School of Veterinary Science, The University of Sydney, Sydney, New South Wales, Australia.
M F ThompsonFaculty of Science, Sydney School of Veterinary Science, The University of Sydney, Sydney, New South Wales, Australia.
B KimbleFaculty of Science, Sydney School of Veterinary Science, The University of Sydney, Sydney, New South Wales, Australia.

Funding

EveryCat Health Foundation W21-006Lionel Marcellus Lonsdale scholarship Supporting Sally Coggins' doctoral thesis
6 · The paper itself

Abstract

objectivesThis study aimed to: (1) characterise the pharmacokinetics of GS-441524 following intravenous (iv) administration of 15 mg/kg remdesivir (RDV) in client-owned cats with feline infectious peritonitis (FIP); (2) document plasma protein binding of GS-441524 in cats; (3) determine whether trough GS-441524 plasma concentrations predict 'simple remission' or survival to 18 months; (4) measure GS-441524 concentration in effusions relative to plasma; and (5) qualitatively assess excretion of GS-441524 in urine. MATERIALS AND

methodsSix cats with FIP were administered 15 mg/kg iv RDV. Serial plasma GS-441524 concentrations were measured using high-performance liquid chromatography (HPLC). Twenty-two cats with FIP had trough plasma concentrations monitored over a 12-week treatment period. Simultaneous effusion and plasma GS-441524 concentrations were compared, and urine was assessed for GS-441524 excretion.

resultsThe mean peak plasma concentration of GS-441524 (C CLINICAL SIGNIFICANCE: This study supports the use of RDV and GS-441524 for FIP treatment and suggests that population pharmacokinetic modelling is required to better explore the utility of therapeutic drug monitoring of GS-441524.

Indexed as

Adenosine MonophosphateAlanineAntiviral AgentsFeline Infectious PeritonitisAdenosineAdenosine TriphosphateAdministration, IntravenousAnimalsCatsDrug MonitoringFemaleMaleAdenosineAdenosine MonophosphateAdenosine TriphosphateAlanineAntiviral AgentsGS-441524GS-441524 triphosphateremdesivir

Identifiers

PMID40097914
PMCPMC12232335

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.